Antisense RNA Agents Targeting HIV-1 Gag for Viral Suppression
Solution Overview
Problem
Current treatments for HIV-1 infection, although effective in preventing AIDS, do not eradicate the virus and are associated with short- and long-term side effects, necessitating alternative therapeutic strategies for long-term viral suppression with minimal adverse effects.
Innovation Solution
Development of antisense nucleic acid molecules, specifically ribozymes and short hairpin RNAs, targeting conserved sequences in the HIV-1 genome, such as the SOFA-HDV-Rz and shRNA1498, which inhibit viral replication by cleaving specific RNA sites, thereby reducing HIV-1 production and replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule therapy is used to treat HIV-1 infection, then viral replication is inhibited, but the treatment is associated with short- and long-term side effects and cannot eradicate the virus
Solution Approach 1:
The invention changes the therapeutic parameter from small molecule inhibitors to nucleic acid-based agents (antisense oligonucleotides, ribozymes, siRNAs, shRNAs) that target specific viral RNA sequences. This parameter change enables more specific viral suppression with reduced off-target effects, addressing the contradiction between efficacy and side effects
Solution Approach 2:
The invention replaces the chemical mechanism of small molecule inhibition with a nucleic acid-based mechanism that uses sequence-specific hybridization and RNA interference pathways. This substitution allows for more precise targeting of viral replication processes, improving reliability while reducing harmful effects on host cells
2Reliability
If antisense nucleic acid molecules are designed to target conserved sequences in HIV-1 genome, then viral replication is inhibited with high specificity, but the design and development complexity increases
Solution Approach 1:
The invention employs multiple types of nucleic acid agents (antisense oligonucleotides, ribozymes, siRNAs, shRNAs) that all function through the universal mechanism of sequence-specific RNA binding and interference. This multi-functionality approach allows targeting of conserved viral sequences with high specificity while utilizing well-established molecular biology principles to manage design complexity
Solution Approach 2:
The invention uses conserved sequences in the HIV-1 genome as intermediary targets that are recognized by various nucleic acid agents. These conserved sequences serve as universal binding sites that mediate the interaction between different types of therapeutic molecules and viral RNA, enabling specific inhibition while simplifying the targeting strategy across different agent types
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These molecules effectively inhibit HIV-1 production across diverse viral strains with minimal off-target effects on human RNAs, providing a potent and specific approach for viral suppression with potential for reduced side effects compared to existing therapies.
Implementation Method 1
An antisense nucleic acid molecule directed against a sequence corresponding to about nucleotide 1495 to about nucleotide 1526 of HIV-1 clone pNL4-3
Implementation Method 2
which is a ribozyme... wherein said ribozyme is a Specific On/Off Adaptor (SOFA) Hepatitis Delta Virus (HDV) ribozyme
Implementation Method 3
which is a short hairpin RNA (shRNA)... which is a small interfering RNA (siRNA)
Data Source
AI summary
Antisense nucleic acid molecules, such as ribozymes, shRNA and siRNA, targeting the Gag region of HIV-1 open reading frame, and uses thereof for inhibiting HIV-1 replication and infection, are disclosed. The antisense nucleic acid molecules more specifically target a sequence corresponding to about nucleotide 1495 to about nucleotide 1526, or nucleotide 1497 to about nucleotide 1521, of HIV-1 clone pNL4-3.